कंपनी का अवलोकन
UroGen Pharma Ltd. is a biotechnology enterprise dedicated to the development and commercialization of innovative solutions specifically targeting urothelial and specialty cancers. The company operates within the broader Healthcare sector, functioning specifically in the Biotechnology industry, which implies a focus on research-intensive drug discovery and regulatory navigation for novel therapies. This organization employs a workforce of 291 individuals to execute its strategic initiatives in oncology treatments. With a market capitalization of $929.83M and annual revenue of $109.79M, the company holds a mid-tier position in the biotechnology landscape. These valuation and revenue figures indicate that the entity has achieved significant commercial traction in its niche market, yet remains a specialized player rather than a diversified pharmaceutical giant.
वित्तीय स्वास्थ्य
The company reported a revenue of $109.79M for the trailing twelve months, accompanied by a net income of $-153,494,000 and an EBITDA of $-124,556,000. The substantial gap between the positive revenue of nearly $110M and the negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs typical of early-stage commercialization phases. Free cash flow stands at $-99,423,000, indicating that the company is currently burning cash rather than generating liquidity, which suggests limited financial flexibility until revenue scales or profitability improves. Gross margin is an impressive 88.7%, while operating margin is negative at -50.5% and profit margin is significantly negative at -139.8%, highlighting the intense pressure on profitability despite efficient production costs. Total cash on hand of $120.46M is slightly lower than total debt of $130.09M, and the debt-to-equity ratio is N/A, suggesting a leveraged balance sheet where liabilities exceed liquid assets. The current ratio is 4.01, which indicates a robust short-term liquidity position capable of covering immediate obligations many times over. Return on Equity is N/A due to the company's capital structure, while return on assets is -32.1%, revealing that the asset base is currently generating negative returns on investment.
मूल्यांकन आकलन
The trailing P/E ratio is N/A because the company is unprofitable, whereas the forward P/E is 20.70, which implies an expectation by the market of future earnings normalization or profitability in the upcoming fiscal periods. The price-to-book ratio is -8.76, indicating that the market values the company at a significant premium over its negative book value, reflecting the intangible value of its proprietary technologies and pipeline. The price-to-sales ratio is 8.47 and the EV/EBITDA is -7.54, suggesting that investors are pricing the stock based on revenue growth potential and strategic assets rather than current earnings power or cash flow generation. The 52-week high is $30.00 and the 52-week low is $3.42, meaning the current price sits at a level that requires calculation relative to this wide range to determine the percentage distance from the highs or lows. The beta value is 1.44, which signifies that the stock's price volatility is 44% higher than the broader market, exposing investors to amplified swings during periods of market stress or sector rotation.
Growth & Income
Revenue growth year-over-year is 54.0%, while earnings growth year-over-year is N/A, indicating that the company is expanding its top line rapidly but has not yet achieved consistent earnings growth to match that velocity. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the organization reinvests all available earnings and cash reserves directly into research, development, and commercial expansion rather than returning capital to shareholders. This reinvestment strategy is typical for biotechnology firms prioritizing pipeline advancement over income distribution. The overall growth and income profile is defined by aggressive revenue expansion coupled with a complete absence of current income generation or dividend payments.